Trials / Completed
CompletedNCT00494481
E3 Breast Cancer Taxotere Combination
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vandetanib (ZD6474) | once daily oral dose |
| DRUG | Docetaxel | intravenous infusion |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-06-01
- Completion
- 2009-01-01
- First posted
- 2007-06-29
- Last updated
- 2016-09-30
- Results posted
- 2011-05-24
Locations
12 sites across 5 countries: Hungary, South Africa, Spain, Sweden, Taiwan
Source: ClinicalTrials.gov record NCT00494481. Inclusion in this directory is not an endorsement.